Waksal Harlan — SEC Form 4 filings
SEC reporting owner CIK 1449008. 3 Form 4 filings on record with FilingPulse; latest filed 2026-07-29.
Transaction summary — filings shown
Covers all 3 filings on record, filed 2024-03-20 to 2026-07-29. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Freenome, Inc. (FRNM) | — | 1 | — | — | 2 |
| Lyra Therapeutics, Inc. (LYRA) | Executive Chair, Director | 2 | — | — | 2 |
Form 4 filings — Waksal Harlan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-29 | 4 | Freenome, Inc. (FRNM) | Conversion (C): 30,000 · Conversion (C): 30,000 (derivative) | EDGAR |
| 2024-12-11 | 4 | Lyra Therapeutics, Inc. (LYRA) | Grant/award (A): 128,333 (derivative) @ $0 | EDGAR |
| 2024-03-20 | 4 | Lyra Therapeutics, Inc. (LYRA) | Grant/award (A): 275,000 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1449008 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →